Displaying 121 - 132 of 452
Liver Tumours
6

Bayer: Evolving horizons in HCC diagnosis and therapy - EASL Liver Cancer Summit 2024

View
Liver Tumours
6

Bayer: Evolving horizons in HCC diagnosis and therapy - EASL Liver Cancer Summit 2024

View
Liver Tumours
6

AstraZeneca: Evolution Of HCC Management: Clinical Considerations For Mdt-Directed Care And Treatment Selection - EASL Liver Cancer Summit 2024

View
Liver Tumours
6

AstraZeneca: Evolution Of HCC Management: Clinical Considerations For Mdt-Directed Care And Treatment Selection - EASL Liver Cancer Summit 2024

View
Liver Tumours
6

AstraZeneca: Evolution Of HCC Management: Clinical Considerations For Mdt-Directed Care And Treatment Selection - EASL Liver Cancer Summit 2024

View
Liver Tumours
4

Roche: Unveiling the key factors: critical aspects in HCC treatment today - EASL Liver Cancer Summit 2024

View
Liver Tumours
4

Roche: Unveiling the key factors: critical aspects in HCC treatment today - EASL Liver Cancer Summit 2024

View
Liver Tumours
4

Roche: Unveiling the key factors: critical aspects in HCC treatment today - EASL Liver Cancer Summit 2024

View
Liver Tumours
4

Roche: Unveiling the key factors: critical aspects in HCC treatment today - EASL Liver Cancer Summit 2024

View
Viral Hepatitis
6

AbbVie: "Test + treat = Cure. Is the HCV elimination formula really that simple?" - EASL Congress 2023

View
Immune-Mediated and Cholestatic Diseases
5

GSK: "Investigating IBAT inhibition in itch – a new tool for an age-old problem?" - EASL Congress 2023

View
Immune-Mediated and Cholestatic Diseases
7

GSK: "Practical tips towards providing holistic care to patients with PBC" - EASL Congress 2023

View
Displaying 121 - 132 of 452